A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study ...
Feb 13, 2024
0
26
An in-depth analysis of two common treatments for advanced pancreatic cancer from The University of Toledo has found the combination chemotherapy drug Folfirinox is more likely to promote progression-free survival—a notable ...
Feb 8, 2024
0
2
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large ...
Jan 29, 2024
0
0
For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS), ...
Jan 29, 2024
0
0
A lack of cancer progression could be used as a substitute for overall survival in metastatic hormone-sensitive prostate cancer clinical trials, according to a new meta-analysis published in the Journal of Clinical Oncology, ...
Jan 26, 2024
0
0
Imaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather than the standard of around three months—identified metabolic changes that corresponded with treatment ...
Jan 24, 2024
0
0
A new study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center shows that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy ...
Jan 11, 2024
0
0
For patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative conditioning regimen (NMAC) is feasible, ...
Dec 20, 2023
0
1
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers ...
Dec 14, 2023
0
0
For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with ...
Dec 13, 2023
0
8
